ARQT vs. SPY
Compare and contrast key facts about Arcutis Biotherapeutics, Inc. (ARQT) and SPDR S&P 500 ETF (SPY).
SPY is a passively managed fund by State Street that tracks the performance of the S&P 500 Index. It was launched on Jan 22, 1993.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ARQT or SPY.
Key characteristics
| ARQT | SPY | |
|---|---|---|
| YTD Return | 217.34% | 26.77% |
| 1Y Return | 385.78% | 37.43% |
| 3Y Return (Ann) | -21.58% | 10.15% |
| Sharpe Ratio | 4.96 | 3.06 |
| Sortino Ratio | 4.32 | 4.08 |
| Omega Ratio | 1.50 | 1.58 |
| Calmar Ratio | 4.61 | 4.44 |
| Martin Ratio | 20.68 | 20.11 |
| Ulcer Index | 21.19% | 1.85% |
| Daily Std Dev | 88.23% | 12.18% |
| Max Drawdown | -95.02% | -55.19% |
| Current Drawdown | -72.28% | -0.31% |
Correlation
The correlation between ARQT and SPY is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
ARQT vs. SPY - Performance Comparison
In the year-to-date period, ARQT achieves a 217.34% return, which is significantly higher than SPY's 26.77% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
ARQT vs. SPY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and SPDR S&P 500 ETF (SPY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
ARQT vs. SPY - Dividend Comparison
ARQT has not paid dividends to shareholders, while SPY's dividend yield for the trailing twelve months is around 1.17%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ARQT Arcutis Biotherapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SPY SPDR S&P 500 ETF | 1.17% | 1.40% | 1.65% | 1.20% | 1.52% | 1.75% | 2.04% | 1.80% | 2.03% | 2.06% | 1.87% | 1.81% |
Drawdowns
ARQT vs. SPY - Drawdown Comparison
The maximum ARQT drawdown since its inception was -95.02%, which is greater than SPY's maximum drawdown of -55.19%. Use the drawdown chart below to compare losses from any high point for ARQT and SPY. For additional features, visit the drawdowns tool.
Volatility
ARQT vs. SPY - Volatility Comparison
Arcutis Biotherapeutics, Inc. (ARQT) has a higher volatility of 18.69% compared to SPDR S&P 500 ETF (SPY) at 3.88%. This indicates that ARQT's price experiences larger fluctuations and is considered to be riskier than SPY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.